$1.47 $0.03 (2.1%)

01:33 PM EDT on 05/21/19

Titan Pharmaceuticals Inc Del (NASDAQ:TTNP)

CAPS Rating: 1 out of 5

A biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cardiovascular disease, bone disease and other disorders.

Current Price $1.47 Mkt Cap $23.7M
Open $1.44 P/E Ratio 0.00
Prev. Close $1.44 Div. (Yield) $0.00 (0.0%)
Daily Range $1.44 - $1.51 Volume 18,989
52-Wk Range $1.18 - $2.45 Avg. Daily Vol.

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

65 Outperform
26 Underperform
 

All-Star Players

5 Outperform
14 Underperform
 

Wall Street

2 Outperform
0 Underperform
 

Top NASDAQ:TTNP Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Carrier (< 20)
Submitted July 06, 2015

Titan has another chance at approval for Probuphine. The FDA rejected the drug in 2013, but after a favorable phase 3 study that wrapped up in the first half of 2015 things are looking up again. Their patented competitive advantage, ProNeura, is the… More

zzlangerhans (99.80)
Submitted November 24, 2016

I may be playing Taps for Titan prematurely, but it's only CAPS and I don't have much to lose. I read over the last earnings call transcript and the tone didn't sound very rosy. Probuphine was launched before the end of the second quarter, yet… More

NASDAQ:TTNP VS S&P 500 (SPY)

Fools bullish on NASDAQ:TTNP are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about TTNP.

Recs

1
Member Avatar Carrier (< 20) Submitted: 7/5/2015 9:58:35 PM : Outperform Start Price: $50.82 NASDAQ:TTNP Score: -181.50

Titan has another chance at approval for Probuphine. The FDA rejected the drug in 2013, but after a favorable phase 3 study that wrapped up in the first half of 2015 things are looking up again. Their patented competitive advantage, ProNeura, is the real foolish reason for investing in the company. They hold a patent until 2024 for an implantable steady release of Dopamine Agonist. In my opinion this is a great growth company. Completely off the radar of many investors.

Recs

0
Member Avatar oscillation (74.80) Submitted: 4/18/2015 9:20:56 PM : Outperform Start Price: $22.77 NASDAQ:TTNP Score: -130.63

nev

Recs

0
Member Avatar Tbyrne025 (< 20) Submitted: 10/22/2013 11:55:43 AM : Outperform Start Price: $26.73 NASDAQ:TTNP Score: -157.94

The scheduled meeting on 11/15/13 with the FDA will be positive.

Leaderboard

Find the members with the highest scoring picks in TTNP.

Score Leader

longtermgrowth09

longtermgrowth09 (34.02) Score: +256.75

The Score Leader is the player with the highest score across all their picks in TTNP.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
longtermgrowth09 34.02 12/17/2009 Underperform 5Y $69.96 -97.90% +158.85% +256.75 0 Comment
IvegotCanines 60.80 10/14/2011 Underperform 5Y $39.60 -96.29% +136.31% +232.60 0 Comment
DorminABC 99.84 3/16/2011 Underperform NS $48.84 -96.99% +126.61% +223.60 0 Comment
mrpiddler 94.31 5/25/2011 Underperform NS $64.35 -97.72% +118.08% +215.80 0 Comment
Table41 94.21 3/28/2011 Underperform 3M $50.16 -97.07% +117.81% +214.88 0 Comment
Dormin111ob 98.37 3/4/2011 Underperform NS $54.12 -97.28% +117.55% +214.83 0 Comment
2nufool 66.76 12/8/2006 Underperform 3W $117.18 -98.75% +115.59% +214.34 0 Comment
goofy4200 79.81 12/12/2006 Underperform NS $104.94 -98.60% +115.51% +214.11 0 Comment
3acrerock 60.95 1/3/2007 Underperform 1Y $107.58 -98.63% +112.60% +211.23 0 Comment
headyinvestor 73.00 3/19/2013 Underperform 5Y $58.91 -97.50% +84.55% +182.05 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackSchneider 79.07 9/30/2007 Outperform NS $72.60 -97.98% +96.80% -194.78 1 Comment
TrackEveillard 93.38 9/30/2007 Outperform NS $72.60 -97.98% +96.80% -194.78 1 Comment

Advertisement